Formosa Pharmaceuticals, Inc. Sustainability Profile
Formosa Pharmaceuticals, Inc., commonly referred to as Formosa Pharma, is a leading biopharmaceutical company headquartered in Taiwan (TW). Established in 2015, the company has rapidly positioned itself within the global pharmaceutical landscape, focusing on the development of innovative therapies for unmet medical needs, particularly in oncology and autoimmune diseases. With a robust pipeline of proprietary products, Formosa Pharma distinguishes itself through its commitment to advanced drug delivery systems and targeted therapies. The company has achieved significant milestones, including successful clinical trials and strategic partnerships that enhance its market presence. Renowned for its dedication to research and development, Formosa Pharmaceuticals continues to make strides in improving patient outcomes and solidifying its reputation as a key player in the biopharmaceutical industry.
DitchCarbon Score
How does Formosa Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Formosa Pharmaceuticals, Inc.'s score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Formosa Pharmaceuticals, Inc.'s reported carbon emissions
Formosa Pharmaceuticals, Inc., headquartered in Taiwan (TW), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Formosa Pharmaceuticals has not established any Science-Based Targets Initiative (SBTi) reduction targets or other significant climate commitments. The lack of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction efforts. However, without specific data or commitments from Formosa Pharmaceuticals, it is challenging to assess their current environmental impact or future climate goals.
How Carbon Intensive is Formosa Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Formosa Pharmaceuticals, Inc.'s Location?
Formosa Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Formosa Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
